Article Text

other Versions

PDF
MYC amplification in breast cancer: a chromogenic in situ hybridisation study
  1. Socorro Maria Rodriguez-Pinilla (pimaso{at}yahoo.es)
  1. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom
    1. Robin L Jones (robin.jones{at}icr.ac.uk)
    1. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom
      1. Maryou BK Lambros (maryou.lambros{at}icr.ac.uk)
      1. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom
        1. Edurne Arriola (edurne.arriola{at}icr.ac.uk)
        1. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom
          1. Kay Savage (kay.savage{at}icr.ac.uk)
          1. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom
            1. Michelle James (michelle.james{at}icr.ac.uk)
            1. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom
              1. Sarah E Pinder (sep43{at}cam.ac.uk)
              1. Department of Histopathology, Addenbrooke's Hospital, Cambridge, UK, United Kingdom
                1. Jorge Sergio Reis-Filho (jorgerf{at}icr.ac.uk)
                1. The Breakthrough Breast Cancer Research Centre, Institute of Cancer Research, London, SW3 6JB, United Kingdom

                  Abstract

                  Aims: To analyse the correlation between MYC amplification and various clinico-pathological features and outcome in a cohort of 245 patients with invasive breast carcinoma treated with surgery followed by anthracycline-based chemotherapy. Given the high prevalence of MYC amplification in tumours of BRCA1 mutation carriers and the similarities between these and sporadic "basal-like" carcinomas, we sought to define the prevalence of MYC amplification in "basal-like" breast carcinomas.

                  Methods: MYC gene copy number was assessed on tissue microarrays containing duplicate cores of 245 invasive breast carcinomas by means of chromogenic in situ hybridisation using SpotLight C-MYC amplification probe and Chromosome 8 Centromeric probe(CEP8). Signals were evaluated at 400x magnification; 30 morphologically unequivocal neoplastic cells in each core were counted for the presence of the gene and CEP8 probes.

                  Results: Amplification was defined as a MYC:CEP8 ratio >2. Signals for both MYC and CEP8 were assessable in 196/245(80%) tumours. MYC amplification was found in 19/196 cases(9.7%) and was not associated with tumour size, histological grade, positivity for oestrogen receptor, progesterone receptor, HER2, epidermal growth factor, cytokeratins 14, 5/6 and 17, MIB1 or p53. Only 4% of basal-like carcinomas showed MYC amplification, compared to 8.75% and 10.7% of luminal and HER2 tumours. On univariate analysis, MYC amplification displayed a significant association with shorter metastasis-free and overall survival and proved to be an independent prognostic factor on multivariate survival analysis.

                  Conclusion: MYC amplification is not associated with "basal-like" phenotype and proved to be an independent prognostic factor for breast cancer patients treated with anthracycline-based chemotherapy.

                  • CISH
                  • MYC
                  • basal-like breast cancer
                  • prognosis
                  • tissue microarrays

                  Statistics from Altmetric.com

                  Request permissions

                  If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.